Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | GUSB | P08236 | 2/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL760930 | 0.89 | TDP1 (0.41) | TDP1KDM4EALDH1A1GUSBHPGD | |
| SCHEMBL758615 | 0.79 | TDP1 (0.45) | TDP1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL753235 | 0.78 | KEAP1 (0.60) | KEAP1GRIA2 | |
| SCHEMBL783237 | 0.75 | TDP1 (0.42) | TDP1MAPTPOLBPKM | |
| SCHEMBL762296 | 0.75 | GRIA2 (0.55) | KEAP1ALDH1A1GRIA2SMN1; SMN2 | |
| SCHEMBL783111 | 0.74 | KEAP1 (0.43) | KEAP1KDM4EALDH1A1GRIA2HPGD | |
| SCHEMBL760979 | 0.74 | KEAP1 (0.48) | KEAP1KDM4EGRIA2POLB | |
| SCHEMBL5477044 | 0.74 | GRIA2 (0.49) | GRIA2BRD4POLB | |
| SCHEMBL1980615 | 0.72 | CNR2 (0.38) | KDM4EGRIA2SMN1; SMN2POLB | |
| SCHEMBL757860 | 0.71 | KEAP1 (0.40) | KEAP1KDM4EALDH1A1GRIA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569285-B2 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-10-29 | — | — | US | disclosed |
| EP-2431360-B1 | Derivatives of dihydrobenzoxathiazepine, method of preparing same and pharmaceutical compositions containing them as well as their uses as modulators of AMPA receptors | SERVIER LAB (FR) | 2013-04-17 | — | — | EP | disclosed |
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-03-22 | — | — | US | disclosed |
| EP-2431360-A1 | Derivatives of dihydrobenzoxathiazepine, method of preparing same and pharmaceutical compositions containing them as well as their uses as modulators of AMPA receptors | Les Laboratoires Servier (FR) | 2012-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | GABRA1, GRM1, GABRA5 | KEAP1 2482/4885TDP1 2079/4885KDM4E 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.